by Shelleygan Petersen

THE Chinese-manufactured Covid-19 vaccine Sinopharm has received clearance for emergency use from the World Health Organisation (WHO).

China donated 100 000 doses of the vaccine to Namibia earlier this year.

The Sinopharm vaccine is produced by the Beijing Bio-Institute of Biological Products.

Vaccines undergo WHO emergency use listing (EUL) assessment to evaluate their quality, safety and efficacy, risk management plans and programme suitability, including factors such as cold-chain requirements.

In the case of the Sinopharm vaccine, the WHO assessment included on-site inspection of the production facility. 

Sinopharm is said to be 79,8% effective.

The WHO recommends the vaccine for adults over 18 years in a two-dose schedule with a spacing of three to four weeks.

The vaccine’s efficacy for symptomatic and hospitalised patients was estimated to be 79% among all age groups. 

Last week, the WHO listed the Moderna vaccine for emergency use, making it the fifth vaccine to receive emergency clearance from the WHO, and Sinopharm the sixth.

Share this